According to a story on the MarketWatch web site yesterday, two not-for-profit organizations have been seeking hearings on revocation of patents held by Medivation on the drug enzalutamide (Xtandi). … READ MORE …
Filed under: Uncategorized | Tagged: cost, enzalutamide, hearing, price, Xtandi | 11 Comments »
In an article published on Monday September 28, in Pharmaceutical Executive (a well-known biopharmaceutical industry trade journal) a senior health care public relations executive recently laid out a detailed rationale for why the industry needs to do a better job … READ MORE …
Filed under: Living with Prostate Cancer | Tagged: access, cost, drug, life, price, survival, value | 5 Comments »
According to an announcement this morning from The Mayo Clinic, a group of 118 leading cancer experts has drafted proposals for reducing the high cost of cancer drugs and voiced support for a patient-based grassroots movement demanding action on the issue. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: advocacy, cost, drug, price | 5 Comments »
A post with the above title by Dr. Mikkael Sekeres of the Cleveland Clinic appeared yesterday on the “Well” blog of The New York Times web site. The patient referred to probably doesn’t have prostate cancer … but the tale is one that too many prostate cancer patients may now have to face.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cost, price | Leave a comment »
As all our regular readers will be well aware, it is not enough, in the UK, for a new cancer drug to be approved for use by the European Union and its European Medicines Agency. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: access, cost, drug, NICE, price, value | 5 Comments »
The news junkies among our readers probably already know this, but …. READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: affordability, cost, drug, price, value | 4 Comments »
As regular readers will be aware, The “New” Prostate Cancer InfoLink regularly notes that the continuing rise in the prices of new drugs for the treatment of prostate cancer (and many other conditions too) is unsustainable. And what we need to do about it is hard to work out. … READ MORE …
Filed under: Uncategorized | Tagged: cost, drug, price, profit | 5 Comments »
There is a very recent and interesting article on a Scientific American blog site called “The Curious Waveform”. It discusses the apparent disconnect between what it costs to manufacture a new drug today and the price we may be asked to pay for it. … READ MORE …
Filed under: Drugs in development | Tagged: cost, drug, price | Comments Off on Why are the prices of new drugs today so high?
In what is being described as “an extraordinary step” in some media reports, a group of more than 100 leukemia specialists has just published an article in the journal Blood asking for a real dialog with the biopharmaceutical industry about the constantly increasing costs associated with new (and older) drugs for the treatment of this form of cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: cancer, cost, drug, price | Leave a comment »
According to recent news reports (such as this one), the UK’s National Institute for Health and Clinical Excellence (NICE) will have full responsibility for determining the “value” of all drug therapies when a new drug pricing system is implemented in the UK in 2014. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management | Tagged: diagnostics, drugs, price, value | 5 Comments »
There has been a lot of speculation as to what Dendreon would charge for a course of treatment with sipuleucel-T (Provenge). For 2 years, The “New” Prostate Cancer InfoLink has been telling readers that we expected this price to be not less than $75,000. … READ MORE …
Filed under: Management, Treatment | Tagged: price, Provenge, sipuleucel-T | 5 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 